ARTICLE
13 March 2024

Holland & Knight Health Dose: March 5, 2024

HK
Holland & Knight
Contributor
Holland & Knight is a global law firm with nearly 2,000 lawyers in offices throughout the world. Our attorneys provide representation in litigation, business, real estate, healthcare and governmental law. Interdisciplinary practice groups and industry-based teams provide clients with access to attorneys throughout the firm, regardless of location.
Holland & Knight Health Dose is an in-depth weekly dose of legislative and regulatory insights to keep stakeholders abreast of happenings in Washington, D.C., impacting the health sector.
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

Holland & Knight Health Dose is an in-depth weekly dose of legislative and regulatory insights to keep stakeholders abreast of happenings in Washington, D.C., impacting the health sector.

This week's topics include:

  • This Week: Markups and Hearings
  • FY 2024 Appropriations Update
  • Health and Public Health Extenders Are Expected in Appropriations Package
  • House Floor Votes Expected on Health Legislation
  • Senate AI Working Group Discusses Health Priorities at Senate Finance Committee Hearing
  • Senate HELP Committee GOP Members Seek Information on STLDI Plans as Final Rule Goes to OMB
  • House E&C Committee's Subcommittee on Health Considers Legislation on Rare Diseases
  • Retirements
  • CMS Interoperability and Prior Authorization Final Rule Education Session
  • PBM Reform Discussions Are Ongoing
  • CMS' 2025 MA and Part D Final Rule at White House Budget Office
  • Biden-Harris Administration Issues Final Guidance to Help People with Medicare Prescription Drug Coverage Manage Prescription Drug Costs
  • 2024 Call for MIPS Improvement Activities is Open
  • ARPA-H Funds AI-Driven Drug Repurposing Project
  • MACPAC Announces March 2024 Public Meeting
  • HHS Health Information Technology Advisory Committee Announces Meeting
  • HRSA Seeks Input on Processes Related to Screening for Heritable Disorders in Newborns and Children
  • Stakeholder Input for NASEM Assessment of NIH Research on Women's Health
  • FTC, DOJ and HHS Launch Private Equity Inquiry

Read the full Health Dose »

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

ARTICLE
13 March 2024

Holland & Knight Health Dose: March 5, 2024

United States Food, Drugs, Healthcare, Life Sciences
Contributor
Holland & Knight is a global law firm with nearly 2,000 lawyers in offices throughout the world. Our attorneys provide representation in litigation, business, real estate, healthcare and governmental law. Interdisciplinary practice groups and industry-based teams provide clients with access to attorneys throughout the firm, regardless of location.
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More